Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 249

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial

Open access
Cella, David, Grünwald, Viktor, Escudier, Bernard, Hammers, Hans J, George, Saby, Nathan, Paul, Grimm, Marc-Oliver, Rini, Brian I, Doan, Justin, Ivanescu, Cristina, Paty, Jean, Mekan, Sabeen, Motzer, Robert J · 2019 · The Lancet Oncology

Abstract

Summary Background In the ongoing phase 3, CheckMate 214 trial, nivolumab plus ipilimumab improved overall survival compared with sunitinib in patients with intermediate or poor risk, previously untreated, advanced renal cell carcinoma. We aimed to assess whether health-related quality of life (HRQoL) could be used to further describe the benefit-risk profile of nivolumab plus ipilimumab versus sunitinib. Methods In the phase 3, randomised, controlled, CheckMate 214 trial, patients aged 18 years and older with previously untreated, advanced or metastatic renal cell carcinoma with a clear-cell component were recruited from 175 hospitals and cancer centres in 28 countries. Patients were categorised by risk status into favourable, intermediate, and poor risk subgroups and randomly assigned (1:1) to open-label nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four doses followed by nivolumab 3 mg/kg every 2 weeks, or sunitinib 50 mg/day for 4 weeks of each 6-week cycle. Randomisation was done with a block size of four and stratified by risk status and geographical region. Patient-reported outcomes (PROs) were assessed using the Functional Assessment of Cancer Therapy Kidney Symptom Index-19 (FKSI-19), Functional Assessment of Cancer Therapy-General (FACT-G), and EuroQol five dimensional three level (EQ-5D-3L) instruments. The coprimary endpoints of the trial, reported previously, were overall survival, progression-free survival, and the proportion of patients who had an objective response in those categorised as at intermediate or poor risk. PROs in all randomised participants were assessed as an exploratory endpoint; here we report this exploratory endpoint. This study is registered with ClinicalTrials.gov, number , and is ongoing but is now closed to recruitment. Findings Between Oct 16, 2014, and Feb 23, 2016, of 1390 patients screened, 1096 (79%) were randomly assigned to treatment, of whom 847 (77%) were at intermediate or poor risk and randomly assigned to nivolumab plus ipilimumab (n=425) or sunitinib (n=422). Median follow-up was 25.2 months (IQR 23.0–274). PROs were more favourable with nivolumab plus ipilimumab than sunitinib throughout the first 103 weeks after baseline, with mean change from baseline at week 103 for FKSI-19 total score being 4.00 (95% CI 1.91 to 6.09) for nivolumab plus ipilimumab versus −3.14 (−6.03 to −0.25) for sunitinib (p<0.0001), and for FACT-G total score being 4.77 (1.73 to 7.82) for nivolumab plus ipilimumab versus −4.32 (−8.54 to −0.11) for sunitinib (p=0.0005). Significant differences were also seen for four of five FKSI-19 domains (disease-related symptoms, physical disease-related symptoms, treatment side-effects, and functional wellbeing) and FACT-G physical and functional wellbeing domains. However, there was no significant difference between the treatment groups at week 103 in EQ-5D-3L visual analogue rating scale (VAS) scores, with mean change from baseline to week 103 of 10.07 (95% CI 4.35 to 15.80) for nivolumab plus ipilimumab and 6.40 (−1.36 to 14.16) for sunitinib (p=0.45). Compared with sunitinib, nivolumab plus ipilimumab reduced risk of deterioration in FKSI-19 total score (hazard ratio [HR] 0.54; 95% CI 0.46–0.63), FACT-G total score (0.63, 0.52–0.75), and EQ-5D-3L VAS score (HR 0.75, 95% CI 0.63–0.89) and UK utility scores (0.67, 0.57–0.80). Interpretation Nivolumab plus ipilimumab leads to fewer symptoms and better HRQoL than sunitinib in patients at intermediate or poor risk with advanced renal cell carcinoma. These results suggest that the superior efficacy of nivolumab plus ipilimumab over sunitinib comes with the additional benefit of improved HRQoL.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(18)30778-2

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 249

Metadata

Authors
Cella, D., Grünwald, V., Escudier, B., Hammers, H. J., George, S., Nathan, P., Grimm, M.-O., Rini, B. I., Doan, J., Ivanescu, C., Paty, J., Mekan, S., & Motzer, R. J.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2019-02
Volume
20
Issue
2
Pages
297-310
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2909056931
Cited by
249
References
7
FWCI
28.66
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. https://app.cochat.ai/papers/10.1016/s1470-2045(18)30778-2
The paper
Cella, D., Grünwald, V., Escudier, B., Hammers, H. J., George, S., Nathan, P., Grimm, M.-O., Rini, B. I., Doan, J., Ivanescu, C., Paty, J., Mekan, S., & Motzer, R. J. (2019). Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(18)30778-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.